Mitsubishi Tanabe Pharma Development America, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$27.2M
Doctors Paid
133
Transactions
1,950
2022 Total
$4.2M
Payment Breakdown by Category
Research$26.4M (96.8%)
Consulting$730,212 (2.7%)
Travel$89,894 (0.3%)
Food & Beverage$31,517 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $26.4M | 927 | 96.8% |
| Consulting Fee | $730,212 | 187 | 2.7% |
| Travel and Lodging | $89,894 | 371 | 0.3% |
| Food and Beverage | $31,517 | 459 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,150 | 1 | 0.0% |
| Honoraria | $1,000 | 2 | 0.0% |
| Education | $169.00 | 3 | 0.0% |
Payments by Type
Research
$26.4M
927 transactions
General
$858,942
1,023 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFECT OF MT-8554 ON THE FREQUENCY AND SEVERITY OF VASOMOTOR SYMPTOMS IN POSTMENOPAUSAL WOMEN | $6.1M | 0 | 73 |
| A Phase II, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of Three Doses of MT-7117 in Patients with Erythropoietic Protoporphyria | $2.5M | 0 | 10 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF MT-7117 IN ADULTS AND ADOLESCENTS WITH ERYTHROPOIETIC PROTOPORPHYRIA OR X-LINKED PROTOPORPHYRIA | $1.8M | 0 | 39 |
| A Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of MT-8554 on the Frequency and Severity of Vasomotor Symptoms in Postmenopausal Women | $1.8M | 1 | 117 |
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF MT-2990 IN WOMEN WITH ENDOMETRIOSIS EXPERIENCING ENDOMETRIAL RELATED PAIN | $1.7M | 0 | 89 |
| A PHASE I, OPEN-LABEL, FOUR-PART, SINGLE-SEQUENCE STUDY TO INVESTIGATE DRUG-DRUG INTERACTION BETWEEN MT-7117 AND TEST DRUGS IN HEALTHY SUBJECTS | $1.7M | 0 | 1 |
| SAFETY STUDY OF ORAL EDARAVONE ADMINISTERED IN SUBJECTS WITH ALS | $1.6M | 0 | 71 |
| A PHASE 3B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE EFFICACY AND SAFETY OF ORAL EDARAVONE ADMINISTERED FOR A PERIOD OF 48 WEEKS IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS ALS | $865,347 | 0 | 32 |
| AN OPEN-LABEL, LONG TERM EXTENSION STUDY OF MT-8554 IN POSTMENOPAUSAL WOMEN EXPERIENCING MODERATE TO SEVERE VASOMOTOR SYMPTOMS WHO COMPLETED STUDY MT-8554-A01 | $754,637 | 0 | 97 |
| A PHASE 3B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE EFFICACY AND SAFETY OF ORAL EDARAVONE ADMINISTERED FOR A PERIOD OF 48 WEEKS IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | $690,776 | 0 | 31 |
| An Open-label, Long Term Extension Study of MT-8554 in Postmenopausal Women Experiencing Moderate to Severe Vasomotor Symptoms Who Completed Study MT-8554-A01 | $658,927 | 0 | 45 |
| A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of MT-2990 in Women with Endometriosis Experiencing Endometrial Related Pain | $639,690 | 0 | 65 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF MT-7117 IN SUBJECTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS | $443,009 | 0 | 29 |
| A STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY , PHARMACOKINETICS OF SINGLE ASCENDING DOSE OF MT-3921 IN SUBJECTS WITH ACUTE SPINAL CORD INJURY | $425,136 | 0 | 23 |
| SAFETY AND EFFICACY STUDY OF MT-2990 IN WOMEN WITH ENDOMETRIOSIS | $423,914 | 0 | 1 |
| A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury | $413,726 | 0 | 21 |
| A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE EFFICACY, SAFETY AND TOLERABILITY OF THREE DOSES OF MT-7117 IN PATIENTS WITH ERYTHROPOIETIC PROTOPORPHYRIA | $372,557 | 0 | 13 |
| A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS) | $343,816 | 0 | 25 |
| A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of MT-3921 in Subjects with Acute Traumatic Cervical Spinal Cord Injury | $336,034 | 0 | 15 |
| Safety and Efficacy Study of MT-2990 in Women With Endometriosis | $329,081 | 0 | 1 |
| EXTENSION STUDY TO EVALUATE SAFETY AND TOLERABILITY OF ORAL DERSIMELAGON (MT-7117) IN SUBJECTS WITH ERYTHROPOIETIC PROTOPORPHYRIA (EPP) OR X-LINKED PROTOPORPHYRIA (XLP) | $327,969 | 0 | 15 |
| STUDY TO ASSESS PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF MT-7117 IN SUBJECTS WITH NORMAL AND IMPAIRED HEPATIC FUNCTION | $322,715 | 0 | 2 |
| A PHASE 3B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND EXTENSION STUDY TO EVALUATE THE CONTINUED EFFICACY AND SAFETY OF ORAL EDARAVONE ADMINISTERED FOR AN ADDITIONAL PERIOD OF UP TO 48 WEEKS FOLLOWING STUDY MT-1186-A02 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | $291,151 | 0 | 14 |
| A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF MT-3921 IN SUBJECTS WITH ACUTE TRAUMATIC CERVICAL SPINAL CORD INJURY | $225,903 | 0 | 13 |
| Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function | $213,833 | 0 | 1 |
| Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | $208,688 | 0 | 6 |
| A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria | $202,902 | 0 | 12 |
| A PHASE 3, MULTI-CENTER, OPEN-LABEL, SAFETY EXTENSION STUDY OF ORAL EDARAVONE ADMINISTERED OVER 96 WEEKS IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS ALS | $194,601 | 0 | 14 |
| A PHASE 3, MULTI-CENTER, OPEN-LABEL, SAFETY EXTENSION STUDY OF ORAL EDARAVONE ADMINISTERED OVER 96 WEEKS IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | $152,267 | 0 | 17 |
| A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered Over 96 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS) | $67,646 | 0 | 15 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Pulmonary Disease | $204,808 | 2 | $102,404 |
| Clinical Genetics (M.D.) | $120,861 | 3 | $40,287 |
| Internal Medicine | $88,849 | 15 | $5,923 |
| Anatomic Pathology | $74,220 | 1 | $74,220 |
| Neurology | $52,716 | 22 | $2,396 |
| Obstetrics & Gynecology | $44,793 | 20 | $2,240 |
| Reproductive Endocrinology | $37,144 | 6 | $6,191 |
| Neurological Surgery | $35,700 | 2 | $17,850 |
| Rheumatology | $32,610 | 5 | $6,522 |
| Gynecology | $25,333 | 6 | $4,222 |
| Anatomic Pathology & Clinical Pathology | $23,513 | 2 | $11,756 |
| Pediatrics | $20,483 | 2 | $10,241 |
| Dermatology | $20,260 | 4 | $5,065 |
| Gastroenterology | $15,442 | 7 | $2,206 |
| Family Medicine | $8,851 | 5 | $1,770 |
| Neuromuscular Medicine | $8,807 | 2 | $4,403 |
| Specialist | $8,720 | 4 | $2,180 |
| Psychiatry | $5,561 | 2 | $2,780 |
| Endocrinology, Diabetes & Metabolism | $3,600 | 1 | $3,600 |
| MOHS-Micrographic Surgery | $3,100 | 1 | $3,100 |
| Cardiovascular Disease | $2,400 | 1 | $2,400 |
| General Practice | $2,151 | 1 | $2,151 |
| Urogynecology and Reconstructive Pelvic Surgery | $2,119 | 1 | $2,119 |
| Urology | $1,800 | 1 | $1,800 |
| Adult Medicine | $1,700 | 1 | $1,700 |
| Neuropathology | $1,600 | 1 | $1,600 |
| Clinical Neurophysiology | $1,514 | 1 | $1,514 |
| Physical Medicine & Rehabilitation | $1,460 | 1 | $1,460 |
| Sleep Medicine | $1,403 | 2 | $701.64 |
| Hematology & Oncology | $1,304 | 2 | $651.81 |
| Pediatric Hematology-Oncology | $500.00 | 1 | $500.00 |
| Hepatology | $328.11 | 2 | $164.06 |
| Emergency Medicine | $117.64 | 1 | $117.64 |
| Hematology | $115.26 | 1 | $115.26 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2018 |
|---|---|---|---|---|
| Revati Shreeniwas, Md, MD | Pulmonary Disease | Stanford, CA | $204,693 | $0 |
| Dr. Robert Desnick, Ph.d., M.d, PH.D., M.D | Clinical Genetics (M.D.) | New York, NY | $117,814 | $0 |
| Pei Hui, Md, MD | Anatomic Pathology | New Haven, CT | $74,220 | $0 |
| Dr. Dinesh Khanna, M.d, M.D | Internal Medicine | Ann Arbor, MI | $42,361 | $0 |
| James Guest, Md, MD | Neurological Surgery | Miami, FL | $34,500 | $0 |
| Daniel Furst, Md, MD | Rheumatology | Inglewood, CA | $22,219 | $0 |
| Mark Stoler, M.d, M.D | Anatomic Pathology & Clinical Pathology | Charlottesville, VA | $22,100 | $0 |
| Dr. James Simon, M.d, M.D | Reproductive Endocrinology | Washington, DC | $21,969 | $0 |
| Dr. Charles Bowden, M.d, M.D | Pediatrics | Chula Vista, CA | $19,983 | $0 |
| Mary Rico, Md, MD | Dermatology | Miami Shores, FL | $17,585 | $0 |
| Lorinda Chung, Md, MD | Internal Medicine | Palo Alto, CA | $14,383 | $0 |
| Dr. Anthony Scialli, Md, MD | Gynecology | Washington, DC | $12,750 | $0 |
| Dr. Gloria Richard-Davis, Md, MD | Obstetrics & Gynecology | Little Rock, AR | $11,740 | $0 |
| David Cornblath, M.d, M.D | Neurology | Lutherville, MD | $10,825 | $0 |
| Dr. Michael Levy, M.d., Ph.d, M.D., PH.D | Neurology | Boston, MA | $10,553 | $0 |
| Herbert Bonkovsky, Md, MD | Gastroenterology | Winston Salem, NC | $9,582 | $0 |
| Dr. John Varga, Md, MD | Internal Medicine | Ann Arbor, MI | $8,326 | $0 |
| James Seibold, Md, MD | Rheumatology | Farmington, CT | $8,312 | $0 |
| John Buster, Md, MD | Reproductive Endocrinology | Providence, RI | $7,600 | $0 |
| Carlayne Jackson, M.d, M.D | Neuromuscular Medicine | San Antonio, TX | $7,425 | $0 |
| Maureen Mayes, M.d, M.D | Internal Medicine | Houston, TX | $6,104 | $0 |
| Dr. Leo Wang, Md, Phd, MD, PHD | Neurology | Seattle, WA | $5,750 | $0 |
| Arthur Waldbaum, Md, MD | Gynecology | Denver, CO | $5,669 | $0 |
| Dr. Susan Mcelroy, Md, MD | Psychiatry | Mason, OH | $4,500 | $0 |
| Unknown Provider | — | — | $4,496 | $0 |
Ad
Top Products
- Radicava $630.70
Payment Categories
- Food & Beverage $31,517
- Consulting $730,212
- Travel & Lodging $89,894
- Research $26.4M
About Mitsubishi Tanabe Pharma Development America, Inc.
Mitsubishi Tanabe Pharma Development America, Inc. has made $27.2M in payments to 133 healthcare providers, recorded across 1,950 transactions in the CMS Open Payments database. In 2022, the company paid $4.2M. The top product by payment volume is Radicava ($630.70).
Payments were distributed across 34 medical specialties. The top specialty by payment amount is Pulmonary Disease ($204,808 to 2 doctors).
Payment categories include: Food & Beverage ($31,517), Consulting ($730,212), Research ($26.4M), Travel & Lodging ($89,894).